Tumor vaccines are therapeutic vaccines that serve to treat cancer diseases and to convey an immune response to cancer cells. Thus, they differ from prophylactic vaccines that are used for the protection against infectious diseases such as the measles, influenza, etc.
| Name | Description | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|---|
|
Zytokin-aktivierte Killerzellen (CIK-Zellen), allogen, ≤ 1x108 CD3+CD56-T-Zellen/kg Körpergewicht in ≤ 100 ml Infusionsdispersion |
Humane, allogene CIK-Zellen in einer vom Spender abhängigen Anzahl an aktivierten CD3+CD25+CD56+ NK-like T-Zellen, CD3+CD56+ NK-like T-Zellen, CD3-CD56+ NK-Zellen, CD19+ B-Zellen, CD14+ Monozyten und anderen Zellen |
Deutsches Rotes Kreuz Blutspendedienst Baden-Württemberg - Hessen gGmbH |
PEI.A.11630.01.1 | 13.06.2014 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 527 in BAnz AT 12.03.2025 B3.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 14.03.2025
